Spravato (esketamine): what it costs, what insurance covers, and where you can get it
An independent reference, not a clinic and not the manufacturer. Updated for the January 2025 approval of Spravato as a monotherapy for treatment-resistant depression — a change most pages on this subject still have wrong.
Last reviewed against the FDA label and SPRAVATO REMS programme materials on .
2 hours
Minimum on-site monitoring after every dose
SPRAVATO REMS requirement
18+
FDA-approved for adults only
FDA prescribing information
2+
Prior antidepressants that must have been inadequate, for the TRD indication
FDA prescribing information
Medical benefit
How it is billed — not your pharmacy benefit
The reason most cost surprises happen
What Spravato is
Spravato is the brand name for esketamine (the active drug, a close chemical relative of ketamine), given as a nasal spray. You do not take it home. You spray it yourself, at a certified healthcare setting, while a healthcare professional watches, and then you stay there to be monitored.
The FDA has approved it for two things, both in adults aged 18 and over:
- Treatment-resistant depression. Depression that has not responded adequately to at least two antidepressant medications in the current episode. Since January 2025, Spravato is approved for this either on its own as a monotherapy, or alongside an oral antidepressant.
- Depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour. For this indication, the label still specifies use in conjunction with an oral antidepressant.
That first point is worth pausing on, because it is the thing most pages on this subject get wrong. Before January 2025, Spravato could only be prescribed for treatment-resistant depression together with an oral antidepressant. The FDA approved it as a standalone monotherapy for that indication on 21 January 2025. A great many clinic pages, directories, and summaries still say Spravato is "always used alongside an oral antidepressant". For treatment-resistant depression, that has not been true since January 2025. It remains true for the acute-suicidal-ideation indication, which is a distinction worth keeping straight when you read anything else about this drug.
Spravato is a Schedule III controlled substance. It is not the same thing as the intravenous ketamine offered by many clinics, which is a different drug preparation used off-label. That difference matters for cost, for coverage, and for where you can get it — we cover it in detail on the provider page.
Why you can't just pick it up at a pharmacy
Spravato is only available through a restricted programme called REMS — a Risk Evaluation and Mitigation Strategy, which is a safety programme the FDA requires for certain medications. In practice, the programme means three things happen every time, in this order.
Certified site, then supervision, then two hours
- You go to a certified treatment centre. The healthcare setting itself has to be certified for Spravato. A pharmacy cannot dispense it to you, and a clinic that is not certified cannot give it to you, whatever else it offers.
- You spray it yourself, under direct supervision. A healthcare professional is present and watches you take each dose.
- You stay and are monitored for at least two hours. Blood pressure is checked, and you are observed for sedation and dissociation before you are allowed to leave. You must not drive for the rest of the day.
The reason for all this is on the label: esketamine can cause sedation, dissociation (a temporary feeling of being detached from yourself or your surroundings), and increases in blood pressure, and it has potential for misuse. The monitoring period exists to catch those effects while someone qualified is watching.
Four practical consequences
This single constraint explains almost everything else about Spravato:
- Your appointment is long. Budget two to two and a half hours, not twenty minutes. Every session.
- Someone else has to drive you home. Not a suggestion — a label instruction. This is worth arranging before you book, not on the day.
- It is billed under your medical benefit, not your pharmacy benefit. Because the drug is administered to you at a facility rather than dispensed to you, it goes through the medical side of your insurance. This is the single most common source of a surprise bill, and the thing most people get wrong when they call their insurer.
- Certified sites are scarcer than clinics advertising ketamine. That is a safety feature, not a limitation, but it does mean "near me" is a genuinely harder question here than for most treatments.
The REMS page covers this in full, for patients and for clinic staff. What to expect walks through an actual visit hour by hour.
Roughly what people pay
| Your coverage | Typical out-of-pocket per session | The main thing that moves it |
|---|---|---|
| Commercial insurance, with the savings programme | Often the lowest out-of-pocket of any route | Whether the programme covers only the drug or also the visit, and its annual cap |
| Commercial insurance, without it | Varies widely with your plan | Your coinsurance rate and whether you have met your deductible |
| Medicare Part B | A coinsurance percentage of the allowed amount | Whether you have supplemental (Medigap) coverage, which can reduce it to near zero |
| Medicaid | Typically $0 to a few dollars where covered | Whether your state covers it at all, and its prior-authorisation criteria |
| No insurance | The full drug cost plus the site fee, per session | The treatment site's own administration fee, which it sets independently |
Every figure on this site is an estimate, not a quote, and is deliberately given as a range. Use the estimator to get a range for your own situation — it takes five clicks, asks for nothing, and will tell you plainly when it cannot give you an honest number.
Find what you came for
What will this cost me?
Estimate a range for your own coverage, and see what actually makes the number move.
Will my insurance cover it?
Payer by payer: what is usually covered, what prior authorisation asks for, and what to do about a denial.
Where can I actually get it?
How to find a genuinely certified treatment centre, and how to check that a clinic really is one.
What is REMS, and what does it ask of me?
The safety programme explained, for patients and for clinic staff enrolling.
Am I even eligible?
The FDA label criteria for both indications, including the January 2025 monotherapy change.
What is a session actually like?
The two hours, dissociation, side effects, and why you cannot drive afterwards.
Does it work?
What the trials found, stated honestly, with the limitations that usually get left out.
Who runs this site?
How it is funded, how it is sourced, and why it is not a provider.
Common questions
- Is this a Janssen / Johnson & Johnson website?
- No. spravato.clinic is an independent information resource. We are not affiliated with Johnson & Johnson or Janssen, we are not a clinic, we are not REMS-certified, and we do not accept paid placements or referral fees.
- Do I still need to take an oral antidepressant with Spravato?
- For treatment-resistant depression, not necessarily. Since January 2025 the FDA has approved Spravato for that indication either as a monotherapy on its own, or alongside an oral antidepressant — your prescriber decides which fits your situation. For the separate indication covering depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour, the label still specifies use in conjunction with an oral antidepressant.
- What does Spravato cost without insurance?
- Paying cash, you are covering two separate things per session: the medication itself, and the treatment site's fee for supervising the dose and monitoring you for two hours afterwards. Both vary, and the site fee is set independently by each clinic. The estimator on the cost page gives a range rather than a single figure, because a single figure would be a guess. If you are uninsured and income-qualifying, the manufacturer runs a patient assistance programme that may provide the medication itself at no cost.
- Does Medicare cover Spravato?
- Generally yes, under Part B, because the drug is administered at a certified site rather than dispensed to you at a pharmacy. You would typically be responsible for Part B coinsurance on the allowed amount, after the Part B deductible. Supplemental (Medigap) coverage can reduce that considerably. Manufacturer copay cards are not available to people with Medicare — federal rules exclude government-insured patients.
- Can I drive myself home after a session?
- No. The FDA label instructs that patients must not drive or operate machinery until the day after the dose, following a restful sleep. Arrange your ride before the appointment rather than on the day — this catches a lot of people out, and it applies to every session, not just the first.
- How long is a Spravato visit?
- Plan for about two to two and a half hours. That is the mandatory two-hour monitoring period after your dose, plus check-in, a baseline blood pressure reading, and the dose itself. The monitoring period is a REMS requirement and is not shortened for people who feel fine.
- How long before you know whether it is working?
- The label and the pivotal trials assess response over the first four weeks of twice-weekly dosing, and prescribers typically reassess at that point. This varies between people, and it is a question for your prescriber rather than something this site can tell you.
- Is Spravato the same as the IV ketamine some clinics offer?
- No. Spravato is esketamine, given as a nasal spray, FDA-approved for two specific indications, and available only at REMS-certified sites. Intravenous ketamine used for depression is a different preparation given off-label, is not part of the REMS programme, and is generally not covered by insurance. A clinic offering IV ketamine may not be able to administer Spravato at all.
Spotted something out of date?
This site's whole claim is that it is current and honest, which only works if errors get fixed. If something here is wrong, out of date, or missing, we would genuinely like to know.
We can’t answer questions about your own diagnosis, medication, or treatment — please ask your prescriber. We also can’t book appointments, check your insurance, or refer you to a clinic.
Get in touch
Sources
- SPRAVATO (esketamine) prescribing information (revised 04/2025) (opens in a new tab) — US Food and Drug Administration
- SPRAVATO (esketamine) approved in the US as the first and only monotherapy for adults with treatment-resistant depression (opens in a new tab) — Johnson & Johnson (manufacturer material)
- SPRAVATO REMS programme (opens in a new tab) — SPRAVATO REMS (manufacturer-operated)
- SPRAVATO REMS certified treatment centre locator (opens in a new tab) — Janssen / Johnson & Johnson (manufacturer material)
- Medicare Part B costs and coinsurance (opens in a new tab) — Centers for Medicare & Medicaid Services
- 988 Suicide & Crisis Lifeline (opens in a new tab) — 988 Suicide & Crisis Lifeline
Last reviewed against the FDA label and SPRAVATO REMS programme materials on .